Figure 4

Kaplan–Meier survival curves of nanoliposomal irinotecan and fluorouracil with leucovorin in the second-line and third- or later-line groups. (a) Comparison of overall survival between the second-line and the third- or later-line groups, (b) Comparison of overall survival among the second-, third-, and fourth-or-later line groups, (c) Comparison of progression-free survival between the second-line and the third-or later-line groups, (d) Comparison of progression-free survival among the second-, third-, and fourth-or-later line groups. HR hazard ratio, CI confidence interval.